Shares of Infinity Pharmaceuticals (Nasdaq:INFI) were gapping down Monday morning with an open price 16.2% lower than Friday's closing price. The stock closed at $26.95 yesterday and opened today's trading at $22.59.
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- Shares of Infinity Pharmaceuticals (Nasdaq: INFI) were gapping down Monday morning with an open price 16.2% lower than Friday's closing price. The stock closed at $26.95 Friday and opened today's trading at $22.59.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
The average volume for Infinity has been 1.2 million shares per day over the past 30 days. Infinity has a market cap of $1.39 billion and is part of the health care sector and drugs industry. Shares are down 23% year to date as of the close of trading on Friday. Infinity Pharmaceuticals, Inc., a drug discovery and development company, focuses on discovering, developing, and delivering medicines to patients for diseases with significant unmet need. TheStreet Ratings rates Infinity as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, weak operating cash flow and poor profit margins. You can view the full Infinity Ratings Report. Get more investment ideas from our investment research center. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more..